TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05783791

Intervention type: DIAGNOSTIC_TEST
Intervention: Newborn Screening Assay
Description: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Newborn Screening Assay
Description: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Newborn Screening Assay
Description: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.
Study: NCT06124573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Study: NCT06324981

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic text messages
Description: The same unidirectional text message will be sent each week for 9 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive AI chatbot text messaging
Description: Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proactive pharmacist support
Description: Pharmacists that will proactively facilitate effective engagement with patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proactive pharmacist support
Description: Pharmacists that will proactively facilitate effective engagement with patients.
Study: NCT06150833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boya IVIG
Description: The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days
Study: NCT05811936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Needs Assessment Planning (SNAP) tool
Description: SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement.
Study: NCT05530317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).
Study: NCT05065203

Intervention type: PROCEDURE
Intervention: planned or unplanned Cesarean, operative, or non operative delivery
Description: All types of delivery
Study: NCT05444075

Intervention type: OTHER
Intervention: a method for communication
Description: the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way.

Intervention type: OTHER
Intervention: a method for communication
Description: the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way.

Intervention type: OTHER
Intervention: a method for communication
Description: the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way.
Study: NCT05909072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid combined with tranexamic acid microneedling
Description: 1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid microneedling
Description: On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
Study: NCT04917731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botox injected at digital artery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botox injected at digital artery
Study: NCT04712669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rodatristat ethyl 300 mg tablet BID
Description: rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rodatristat ethyl 600 mg BID
Description: 2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matching placebo tablets on top of standard of care
Study: NCT05208450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice support And Community Engagement (PACE)
Description: A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
Study: NCT04944758

Intervention type: DEVICE
Group type: OTHER
Intervention: Light therapy
Description: Light therapy
Study: NCT04873843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional digital game training group
Description: Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual cognitive training
Description: Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
Study: NCT05364112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compreflex
Description: The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
Study: NCT05990166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral-enriched powder
Description: Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
Study: NCT04681365

Intervention type: OTHER
Intervention: Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)
Description: Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)

Intervention type: OTHER
Intervention: Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)
Description: Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)

Intervention type: OTHER
Intervention: Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)
Description: Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
Study: NCT06340776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
Study: NCT05391620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with 3/7 method
Description: HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned.
Study: NCT04867824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Case (use of inhaled vanilla essential oil)
Description: Use of inhaled vanilla essential oil during frenotomy for a tongue-tie

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (use of inhaled lavender essential oil)
Description: Use of inhaled lavender essential oil during frenotomy for a tongue-tie
Study: NCT05391620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with 3/7 method
Description: HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with 3X9 method
Description: HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with 3X9 method
Description: HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned
Study: NCT06413693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: A single dose of PF-07293893 administered orally as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: A single dose of PF-07293893 administered orally as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of Placebo administered orally as tablets that look the same as PF-07293893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of Placebo administered orally as tablets that look the same as PF-07293893
Study: NCT04579198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)
Description: The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
Study: NCT05078255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.34 MG/ML [Ozempic]
Description: Semaglutide 1.34 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.34 MG/ML [Ozempic]
Description: Semaglutide 1.34 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic polypeptide (GIP)
Description: GIP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic polypeptide (GIP)
Description: GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.34 mg/ml placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide 1.34 mg/ml placebo
Description: Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GIP placebo
Description: Saline
Study: NCT06465485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
Study: NCT05674929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-003
Description: A single dose administered intranasally
Study: NCT05224765

Intervention type: OTHER
Intervention: Fall prevention class
Description: Participants attend fall prevention discharge class per hospital protocols
Study: NCT05460793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopy-guided surgery
Description: The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
Study: NCT05143996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-049
Description: \[FLT3\] x \[CD3\] bispecific T cell engager

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-049
Description: \[FLT3\] x \[CD3\] bispecific T cell engager

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-049
Description: \[FLT3\] x \[CD3\] bispecific T cell engager
Study: NCT05406765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Injection
Description: One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
Study: NCT04974567

Intervention type: OTHER
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study: NCT05629793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental tests
Description: Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental tests
Description: Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
Study: NCT06263881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT04672967

Intervention type: DIAGNOSTIC_TEST
Intervention: BioROSA MAP test
Description: The BioROSA MAP test is a blood test that is being developed to predict ASD risk

Intervention type: DIAGNOSTIC_TEST
Intervention: BioROSA MAP test
Description: The BioROSA MAP test is a blood test that is being developed to predict ASD risk